Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nyse  >  Johnson & Johnson    JNJ

Mes dernières consult.
Most popular
News SummaryMost relevantAll newsSector newsTweets

Johnson & Johnson : Says Discounts Cut the Prices for Its Drugs, Though Revenue Rose

share with twitter share with LinkedIn share with facebook
share via e-mail
03/09/2018 | 12:39am CET

By Jonathan D. Rockoff

Johnson & Johnson said Thursday the average price paid for its medicines in the U.S. fell by 4.6% last year due to the company's discounts, and the company's pharmaceuticals chief expects the pricing pressures on drugmakers will continue this year.

J&J, one of the biggest sellers of prescription drugs in the U.S., said it raised the list prices for its medicines by an average 8.1%, but they wound up as a whole costing far less because the manufacturer handed out $15 billion in discounts and rebates.

"That shows the level of competition that exists in the U.S. market," Joaquin Duato, who heads J&J's pharmaceuticals business, said in an interview.

Overall J&J's U.S. pharmaceutical sales still did well last year, rising 6.7% to $21.5 billion. Mr. Duato said that the increase stemmed from higher volume, not prices.

Several drugmakers provide aggregate pricing data each year partly to blunt public criticism of rising drug prices and shift focus to health-care companies like drug-benefit managers that can profit from the price increases as well as from raising the copays patients pay for medicines.

Merck & Co. said last month that the prices of its drugs and vaccines fell 1.9% in the U.S. last year after discounts and rebates.

Mr. Duato attributed the pricing squeeze to three factors that he expects to keep the drug industry's prices after discounts "flat" this year.

Health plans and drug-benefit managers are "more aggressive" restricting access to expensive drugs, and drug companies are required to provide discounts to growing numbers of patients in Medicaid and hospitals in a drug-discount program known as 340(b), Mr. Duato said.

Lower-priced competition is also starting to have an impact on the pricing of biotechnology drugs, Mr. Duato said, as rivals start launching so-called biosimilar copies.

J&J's aggregate drug pricing last year reflected the impact of such competition for rheumatoid-arthritis treatment Remicade, which has been the company's top-selling product but began facing competition from a copy sold by Pfizer Inc. in late 2016.

Remicade's U.S. sales fell $317 million to $4.5 billion last year.

Remicade competition was a "big factor" in J&J's average net price drop last year "but it wasn't the only factor," Mr. Duato said. The average price for J&J's prescription drugs after discounts was negative in 2017 excluding Remicade, he said.

Some analysts had expected a bigger drop in U.S. Remicade sales than what J&J experienced, but said J&J had managed to hold on to much of its Remicade business in the U.S. by offering deep discounts and other perks to limit switching to the rival drug.

Pfizer has sued J&J alleging it thwarted the "biosimilar" competition through "exclusionary contracts" with health insurers, hospitals and clinics. J&J has said the lawsuit lacks merit.

Write to Jonathan D. Rockoff at [email protected]

share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on JOHNSON & JOHNSON
03/21Britain's use of copycat biotech drugs takes off while U.S. lags
03/21JOHNSON & JOHNSON : Corporate Presenter Harriet Stein Promotes Mindful Leadershi..
03/21JOHNSON & JOHNSON : Cleveland federal judge's ambitious goal to settle hundreds ..
03/20JOHNSON & JOHNSON : Change in Directors or Principal Officers, Financial Stateme..
03/20JOHNSON & JOHNSON : Dominic J. Caruso to Retire as Chief Financial Officer of Jo..
03/20NEW RESEARCH REPORT ON INTERNET OF T : Global Internet of Things for Diabetes Ma..
03/20JOHNSON & JOHNSON : to Host Investor Conference Call on First-Quarter Results
03/20Global Brands Divided Over Transparency Efforts to Tackle Deforestation for P..
03/20JOHNSON & JOHNSON : FDA shares data from first drug in transparency pilot
03/20JOHNSON & JOHNSON : unveils plans for second turbine at Limerick facility
More news
News from SeekingAlpha
03/21Arena's Positive Phase 2 Ulcerative Colitis Data Is An Added Bonus 
03/21Vistagen - Nanocap CNS Drug Chasing Ketamine Fame 
03/21FDA OKs Sun Pharma's Ilumya for plaque psoriasis 
03/21Geron's Imetelstat Hits A Grand Slam, But The Rally Is Just Beginning 
03/20Johnson & Johnson finance chief to retire in September 
Financials ($)
Sales 2018 81 115 M
EBIT 2018 24 940 M
Net income 2018 19 683 M
Debt 2018 12 439 M
Yield 2018 2,77%
P/E ratio 2018 18,08
P/E ratio 2019 16,97
EV / Sales 2018 4,46x
EV / Sales 2019 4,12x
Capitalization 349 B
Duration : Period :
Johnson & Johnson Technical Analysis Chart | JNJ | US4781601046 | 4-Traders
Technical analysis trends JOHNSON & JOHNSON
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 22
Average target price 150 $
Spread / Average Target 15%
EPS Revisions
Alex Gorsky Chairman & Chief Executive Officer
Dominic J. Caruso Chief Financial Officer & Vice President
Paulus Stoffels Chief Scientific Officer & Executive VP
Charles O. Prince Independent Director
William David Perez Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON & JOHNSON-6.79%349 387
PFIZER0.30%216 268
NOVARTIS-5.90%213 387
ROCHE HOLDING LTD.-10.99%199 363
MERCK AND COMPANY-2.90%147 293
AMGEN4.97%131 539